香雪製藥(300147.SZ):股東崑崙投資擬3.95億元轉讓9.9794%股份予恆數一號
格隆匯3月10日丨香雪製藥(300147.SZ)公佈,公司持股5%以上股東廣州市崑崙投資有限公司(“崑崙投資”)與恆數一號於2021年3月9日簽署了《廣州市崑崙投資有限公司與廣東恆數一號投資合夥企業(有限合夥)關於轉讓廣州市香雪製藥股份有限公司股份之股份轉讓協議》(“《股份轉讓協議》”),崑崙投資將公司6600萬股,佔總股本9.9794%,協議轉讓給恆數一號,轉讓價格為5.98元/股,轉讓價款為人民幣約3.95億元。此次協議轉讓完成後,恆數一號將成為公司持股5%以上的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.